Literature DB >> 12021371

Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.

Sampa Santra1, Dan H Barouch, Marcelo J Kuroda, Jörn E Schmitz, Georgia R Krivulka, Kristin Beaudry, Carol I Lord, Michelle A Lifton, Linda S Wyatt, Bernard Moss, Vanessa M Hirsch, Norman L Letvin.   

Abstract

Although recent evidence has confirmed the importance of cytotoxic T-lymphocyte (CTL) responses in controlling human immunodeficiency virus type 1 and simian immunodeficiency virus replication, the relevance of the epitopic breadth of those CTL responses remains unexplored. In the present study, we sought to determine whether vaccination can expand CTL populations which recognize a repertoire of viral epitopes that is greater than is typically generated in the course of a viral infection. We demonstrate that potent secondary CTL responses to subdominant epitopes are rapidly generated following a pathogenic simian-human immunodeficiency virus challenge of rhesus monkeys vaccinated with plasmid DNA or recombinant modified vaccinia virus Ankara vaccines. These data indicate that prior vaccination can increase the breadth of the CTL response that evolves after an AIDS virus infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021371      PMCID: PMC136231          DOI: 10.1128/jvi.76.12.6376-6381.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.

Authors:  T M Allen; T U Vogel; D H Fuller; B R Mothé; S Steffen; J E Boyson; T Shipley; J Fuller; T Hanke; A Sette; J D Altman; B Moss; A J McMichael; D I Watkins
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

2.  Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys.

Authors:  Sampa Santra; Jörn E Schmitz; Marcelo J Kuroda; Michelle A Lifton; Christine E Nickerson; Carol I Lord; Ranajit Pal; Genoveffa Franchini; Norman L Letvin
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

3.  Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.

Authors:  D H Barouch; A Craiu; S Santra; M A Egan; J E Schmitz; M J Kuroda; T M Fu; J H Nam; L S Wyatt; M A Lifton; G R Krivulka; C E Nickerson; C I Lord; B Moss; M G Lewis; V M Hirsch; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Authors:  Dan H Barouch; Jennifer Kunstman; Marcelo J Kuroda; Jörn E Schmitz; Sampa Santra; Fred W Peyerl; Georgia R Krivulka; Kristin Beaudry; Michelle A Lifton; Darci A Gorgone; David C Montefiori; Mark G Lewis; Steven M Wolinsky; Norman L Letvin
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

5.  Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.

Authors:  T Hanke; R V Samuel; T J Blanchard; V C Neumann; T M Allen; J E Boyson; S A Sharpe; N Cook; G L Smith; D I Watkins; M P Cranage; A J McMichael
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys.

Authors:  M D Miller; H Yamamoto; A L Hughes; D I Watkins; N L Letvin
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

7.  Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.

Authors:  D H Barouch; S Santra; M J Kuroda; J E Schmitz; R Plishka; A Buckler-White; A E Gaitan; R Zin; J H Nam; L S Wyatt; M A Lifton; C E Nickerson; B Moss; D C Montefiori; V M Hirsch; N L Letvin
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge.

Authors:  Y Yasutomi; S Koenig; R M Woods; J Madsen; N M Wassef; C R Alving; H J Klein; T E Nolan; L J Boots; J A Kessler
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  7 in total

1.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

Authors:  Lucy Dorrell; Hongbing Yang; Beatrice Ondondo; Tao Dong; Kati di Gleria; Annie Suttill; Christopher Conlon; Denise Brown; Patricia Williams; Paul Bowness; Nilu Goonetilleke; Tim Rostron; Sarah Rowland-Jones; Tomás Hanke; Andrew McMichael
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies.

Authors:  Jinyan Liu; Bonnie A Ewald; Diana M Lynch; Anjali Nanda; Shawn M Sumida; Dan H Barouch
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

4.  Clonal focusing of epitope-specific CD8+ T lymphocytes in rhesus monkeys following vaccination and simian-human immunodeficiency virus challenge.

Authors:  Pritha Sen; William A Charini; Ramu A Subbramanian; Edwin R Manuel; Marcelo J Kuroda; Patrick A Autissier; Norman L Letvin
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

5.  Diverse cross-reactive potential and Vbeta gene usage of an epitope-specific cytotoxic T-lymphocyte population in monkeys immunized with diverse human immunodeficiency virus type 1 Env immunogens.

Authors:  Sandrine L Hulot; Michael S Seaman; Pritha Sen; Patrick A Autissier; Edwin R Manuel; Norman L Letvin
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

6.  Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

Authors:  Yoshiaki Nishimura; Tatsuhiko Igarashi; Nancy L Haigwood; Reza Sadjadpour; Olivia K Donau; Charles Buckler; Ron J Plishka; Alicia Buckler-White; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-19       Impact factor: 11.205

7.  Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen.

Authors:  Paul F McKay; Alethea V Cope; Jamie F S Mann; Sarah Joseph; Mariano Esteban; Roger Tatoud; Darrick Carter; Steven G Reed; Jonathan Weber; Robin J Shattock
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.